But to dismiss this ery detailed report that looks beyond pure usage data and tries to assess outcomes in three different ways is premature and petulant.

• 除了这些新抗癌药的详细的使用数据报告，用三个不同方法试图评估癌症生存率是不成熟的，难以令人信服的。